TY - JOUR
T1 - Clinical manifestations and outcomes of patients with intravascular large B-cell lymphoma with neurological involvement
T2 - highlighting longitudinally extensive myelopathy as a distinct feature
AU - Uawithya, Ekdanai
AU - Lertsakworakul, Palakorn
AU - Owatthanapanich, Weerapat
AU - Jitprapaikulsan, Jiraporn
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2025.
PY - 2025/1/4
Y1 - 2025/1/4
N2 - Objective This study aimed to elucidate the clinical manifestations, laboratory findings and outcomes of patients with intravascular large B cell lymphoma (IVLBCL) with neurological involvement and to differentiate IVLBCL with and without neurological involvement. Methods A cohort study was conducted at Siriraj Hospital, Mahidol University, Thailand, between January 2005 and September 2024. Clinical data, laboratory values and central nervous system imaging results were analysed. Categorical variables were compared using the χ2 or Fisher’s exact test, while continuous variables were analysed with the Mann-Whitney U test, as appropriate. Results Of the 30 patients with IVLBCL, 10 had neurological involvement and 20 without neurological symptoms, including myelopathy (5 patients, 50%); cognitive impairment (3 patients, 30%); seizures (2 patients, 20%); optic neuropathy, hemiparesis, homonymous hemianopia, vertigo and global aphasia (each affecting 1 patient, 10%). 60% of IVLBCL with neurological involvement had systemic symptoms, including prolonged fever, anaemia, anorexia and weight loss. MRI showed hyperintense lesions in the supratentorial, infratentorial and spinal cord with the prominent findings being longitudinally extensive cord lesions (four patients, 40.0%). The median survival time of the IVLBCL with neurological involvement was 4.1 months (95% CI: 0.0 to 17.1 months), with a 1-year survival rate of 37.5% and a 2-year survival rate of 25.0%. Interpretation This study highlights the distinct clinical, laboratory features and imaging of IVLBCL with neurological involvement and compares it to IVLBCL without neurological involvement. Early recognition of these findings is crucial for accurate diagnosis and improved patient outcomes despite the aggressive nature of IVLBCL.
AB - Objective This study aimed to elucidate the clinical manifestations, laboratory findings and outcomes of patients with intravascular large B cell lymphoma (IVLBCL) with neurological involvement and to differentiate IVLBCL with and without neurological involvement. Methods A cohort study was conducted at Siriraj Hospital, Mahidol University, Thailand, between January 2005 and September 2024. Clinical data, laboratory values and central nervous system imaging results were analysed. Categorical variables were compared using the χ2 or Fisher’s exact test, while continuous variables were analysed with the Mann-Whitney U test, as appropriate. Results Of the 30 patients with IVLBCL, 10 had neurological involvement and 20 without neurological symptoms, including myelopathy (5 patients, 50%); cognitive impairment (3 patients, 30%); seizures (2 patients, 20%); optic neuropathy, hemiparesis, homonymous hemianopia, vertigo and global aphasia (each affecting 1 patient, 10%). 60% of IVLBCL with neurological involvement had systemic symptoms, including prolonged fever, anaemia, anorexia and weight loss. MRI showed hyperintense lesions in the supratentorial, infratentorial and spinal cord with the prominent findings being longitudinally extensive cord lesions (four patients, 40.0%). The median survival time of the IVLBCL with neurological involvement was 4.1 months (95% CI: 0.0 to 17.1 months), with a 1-year survival rate of 37.5% and a 2-year survival rate of 25.0%. Interpretation This study highlights the distinct clinical, laboratory features and imaging of IVLBCL with neurological involvement and compares it to IVLBCL without neurological involvement. Early recognition of these findings is crucial for accurate diagnosis and improved patient outcomes despite the aggressive nature of IVLBCL.
KW - CLINICAL NEUROLOGY
KW - LYMPHOMA
KW - NEURO-ONCOLOGY
UR - http://www.scopus.com/inward/record.url?scp=85215657414&partnerID=8YFLogxK
U2 - 10.1136/bmjno-2024-000915
DO - 10.1136/bmjno-2024-000915
M3 - Article
AN - SCOPUS:85215657414
SN - 2632-6140
VL - 7
JO - BMJ Neurology Open
JF - BMJ Neurology Open
IS - 1
M1 - e000915
ER -